NEUROPATHY ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE

与葡萄糖耐量受损相关的神经病

• 批准号: 7604951
• 负责人: John Robinson Singleton
• 金额: $ 2.19万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604951
• 关键词: Age; Clinical; Computer Retrieval of Information on Scientific Projects Database; Count; Defect; Developed Countries; Developing Countries; Diabetes Mellitus; End Point; Epidemiologic Studies; Fiber; Frequencies; Funding; General Population; Glucose; Grant; Histologic; Hyperglycemia; Institution; Insulin Resistance; Measures; Morbidity - disease rate; Natural History; Nerve Fibers; Neurologic; Neuropathy; Pain; Patients; Peripheral Nervous System Diseases; Phenotype; Pilot Projects; Reporting; Research; Research Personnel; Resources; Source; Syndrome; United States National Institutes of Health; cardiovascular risk factor; diet and exercise; double-blind placebo controlled trial; glucose metabolism; impaired glucose tolerance; prevent; prospective; sensory neuropathy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Sensory neuropathy, often with pain, is a common neurologic problem. In developed countries, type II (insulin resistant) diabetes is the most frequently defined cause of sensory neuropathy. We have found that 35-50% of prospectively evaluated patients with otherwise idiopathic painful peripheral neuropathy have impaired glucose tolerance (IGT), an intermediate defect in glucose metabolism which correlates with insulin resistance syndrome, and has been shown to carry an independent risk for cardiovascular morbidity. This is a significantly greater frequency of IGT than reported in large epidemiologic studies of age matched general population (14%). We hypothesize that the postprandial hyperglycemia identified by IGT causes or contributes to a painful, small fiber neuropathy that is indistinguishable from that observed in early frank diabetes, and that early, aggressive treatment of IGT patients to normalize hyperglycemia will slow or prevent progression of neuropathy. This clinical pilot study will lay the groundwork for a later prospective double blind placebo controlled trial of patients with IGT and neuropathy to determine if treatment with intensive diet and exercise cousneling, or a glucose loweing agent can stabilize or reverse neuropathy. In this initial study we will: Characterize the clinical, electrodiagnostic, and histologic phenotype of neuropathy associated with IGT. Define the natural history of IGT associated neuropathy progression using validated endpoint measures, and Validate the use of intraepidermal nerve fiber counting (IENF) as a measure of small fiber loss.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 感觉神经病通常疼痛，是一个常见的神经系统问题。在发达国家，II型（抗胰岛素）糖尿病是感觉神经病的最常见原因。我们发现，有35-50％的前瞻性评估患者否则特发性疼痛的外周神经病患有葡萄糖耐受性（IGT），这是一种与葡萄糖代谢相关的中间缺陷，与胰岛素抵抗综合征相关，并已显示出具有独立的心血管血管症风险。发病率。在大型流行病学研究中，IGT的频率明显高于与普通人群相匹配的大型流行病学研究（14％）。我们假设通过IGT原因鉴定出的餐后高血糖或导致痛苦的小纤维神经病，与早期Frank糖尿病中观察到的疼痛，小纤维神经病以及IGT早期治疗的IGT患者可以使高血糖症归一化的高血糖会减慢或预防神经性神经性神经病的进展减慢或预防。这项临床初步研究将为IGT和神经病患者的后来前瞻性双盲安慰剂对照试验奠定基础，以确定强烈饮食和运动式辅助治疗或葡萄糖降低剂是否可以稳定或反向神经病。在这项最初的研究中，我们将： 表征与IGT相关的神经病的临床，电诊断和组织学表型。 使用经过验证的终点测量和 验证使用压皮内神经纤维计数（IENF）作为小纤维损失的量度。